Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Impact · against what's priced in

Tyra Biosciences is raising $400 million to fund its 'dabogratinib 3x3' clinical strategy, which provides a significant cash runway for its pipeline development. While the equity offering causes immediate shareholder dilution, the strong participation from institutional investors like RA Capital and Janus Henderson signals market confidence in the company's assets.

TYRA+0.10: No priced-in read yet

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

What matters in this story

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

What matters in this story

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

How each ticker is affected

Connected tickers

Track these names every morning.

OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

ANAVEX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

What matters in this story

Next reads from the same story arc

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

What matters in this story

Next reads from the same story arc

Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs

How each ticker is affected

Connected tickers

Track these names every morning.

OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX

ANAVEX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit